/Investor DB

Blackstone Life Sciences

Private equityoperating company · company profile

ABlackstoneventure arm

New York · Series A–Late Stage · 79 people tracked

Also known as BLACKSTONE ALTERNATIVE ASSET MANAGEMENT L.P. · BLACKSTONE ALTERNATIVE CREDIT ADVISORS LP · BLACKSTONE ALTERNATIVE INVESTMENT ADVISORS LLC · BLACKSTONE ALTERNATIVE SOLUTIONS L.L.C. · BLACKSTONE ASSET BASED FINANCE ADVISORS LP · BLACKSTONE CLO MANAGEMENT LLC (MANAGEMENT SERIES)

Find your way into Blackstone Life Sciences

727 people in our graph can introduce you to the Blackstone Life Sciences team.

Sign up to see every warm intro you have to Blackstone Life Sciences

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Blackstone Life Sciences team. We find them
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

✨ Fox Verdict
Sign up to see your fit

Investment thesis

BXLS aims to bring vital medicines and technologies to market by designing, funding and executing clinical trials for products generally in late-stage development. It seeks to fill a funding void in the life sciences industry by collaborating with leading pharmaceutical, biotechnology and medical technology companies to advance their critical-path products to patients. BXLS combines clinical, commercial and operational expertise with Blackstone's global network, capital access and infrastructure to select, fund and advance promising products and companies. Its strategy targets attractive, largely market- and interest-rate-uncorrelated returns at lower risk by capturing value directly from the products it funds rather than from equity exposure.

Source: firm website, verified Sep 29, 2026.

Stage
Series A–Late Stage
Check
$20M – $60M
HQ
New York, Massachusetts, US
Instruments
Equity · Debt
Founded
1985
Last 12 months
3 investments
AUM
$20.1B
Tracked investments
20
Unicorns
4
IPOs
2
Acquisitions
1

Team · 79 people

from the firm's website & curated & public directories
Gautam Banerjee· Sr. Managing Directorin

Senior Managing Director and Chairman of Blackstone Singapore.

Ari Brettman· Senior Managing Director
M. Craig Shepherd· Senior Managing Directorin
Paris Panayiotopoulos· Senior Managing Directorin
Robert Liptak· Senior Managing Directorin
Racim Allouani· Managing Directorin

Managing Director and Head of Portfolio Management at BXPE. He previously spent 10 years at KKR.

Alicia Novak· Executive Officer
Chris Placca· Executive Officer
Christopher Striano· Executive Officer
Elsa Gelin· Executive Officer
Eric Liaw· Executive Officer
Ilan Halal· Executive Officer
Mathias Favetto· Executive Officerin
Matthew Skurbe· Executive Officer
Nentcho Nentchev· Executive Officerin
Victoria Portnoy· Executive Officer

59 people who came through Blackstone Life Sciences went on to found or lead other companies.

+ 47 more →

What they invest in

from 16 of 20 portfolio companies

Biotech ×7SaaS ×6Healthtech ×5Medical Devices ×4Enterprise Software ×3Fintech ×2InsurTech ×2Marketplaces ×2

HQs:United States×6

Investments · 20 tracked

founders shown can be your intro path

By year:2026 · 32025 · 12024 · 12020 · 22019 · 12016 · 19 dated

Alnylam Pharmaceuticalsalnylam.comin𝕏NASDAQ: ALNY

Alnylam is a biopharmaceutical company that supports investigator-initiated studies in therapeutic areas including transthyretin-mediated amyloidosis, acute hepatic porphyria, and primary hyperoxaluria for medical researchers and healthcare professionals.

BiotechDigital HealthMedical DevicesCambridge, US

John Maraganore(Founder)inPhillip Sharp(Founder)David Bartel(Founder)Thomas Tuschl(Founder)Paul Schimmel(Founder)Phillip Zamore(Founder)

Co-investorsARCH Venture PartnersAtlas VentureCardinal PartnersInvivo Capital PartnersAlexandria

Apogee Therapeuticsapogeetherapeutics.cominNASDAQ: APGE

Apogee Therapeutics develops engineered antibody therapies to treat inflammatory and immune diseases with reduced injection frequency compared to existing treatments.

BiotechHealthtechMedical Devices

Michael Henderson(Chief Executive Officer and Director)in

Co-investorsAccess BiotechnologyRA CapitalWellington ManagementPerceptive Xontogeny VentureRTW Investments L.P.Venrock Healthcare Capital Partners

AvenCellavencell.comin𝕏Oct 2024 · $112M✓ verified

AvenCell Therapeutics develops next-generation cell therapies for hard-to-treat cancers, including solid tumors, combining switchable universal CAR-T technology with a CRISPR/Cas9-based allogeneic platform.

BiotechLongevityMedical Devices

Andrew Schiermeier(Chief Executive Officer)in

Co-investorsNovo HoldingsEight Roads VenturesF-Prime CapitalNYBC Ventures

Anagramgoanagram.comMay 2026 · $250M

Anagram provides insurance administration and revenue cycle management software and billing services for eye care practices, covering eligibility and benefits verification, claim submission and scrubbing, denial management, and payment reconciliation across both vision and medical insurance.

HealthtechInsurTechSaaS

Co-investorsFundersClubWaterline VenturesHealthy VenturesKEC VenturesKickstartNextView Ventures

Anagramanagram.care𝕏May 2026 · $250M

Anagram builds software to help eye care providers manage vision insurance, lab ordering, and administrative workflows so they can deliver better patient care affordably.

Enterprise SoftwareHealthtechInsurTechSaaS

Austin Winfield(Founder)in

Co-investorsGreatPoint VenturesHealthy VenturesManchesterStory Group, LLCKEC VenturesKickstartNextView Ventures+1 more

Anagramanagram.xyzMay 2026 · $250M

Anagram describes itself as an institution focused on crypto and the "ownership economy," offering staking services and deploying human and financial capital in the space.

Crypto & Web3

Austin Winfield(Founder)in

Co-investorsMarin Digital VenturesHealthy VenturesKEC VenturesKickstartNextView VenturesWaterline Ventures

Annexonannexonbio.comin𝕏Jul 2020 · $100M

Annexon Bio develops early complement inhibitors that target C1q, the initiating molecule of the classical complement pathway, to treat autoimmune, neurodegenerative, and ophthalmic diseases.

BiotechHealthtechSo. San Francisco, US

Ben Barres(Scientific Co-Founder)Douglas Love(Founder)inMark L Smith(Executive Officer)Campbell Murray(Director)inThomas Wiggans(Director)Ricky Sun(Director)

Co-investorsBain Capital Life SciencesCorrelation VenturesNew Enterprise Associates (NEA)BlackRockClarus VenturesDeerfield Management Company+2 more

Bannerwithbanner.cominSeries A

Banner provides a centralized platform that consolidates communications, workflows, and document management for commercial real estate teams across the acquisition and disposition lifecycle, reducing administrative overhead.

MarketplacesPropTechSaaSNew York City, US

Kunal Chaudhary(Founder)inEric Gao(Founder)inMark Murphy(Founder)

Co-investorsAmino CapitalBasis Set VenturesPruVen Capital PartnersSidekick PartnersY CombinatorContrary+2 more

Engineengine.comin𝕏

Engine (formerly Hotel Engine) operates a business travel management platform that connects companies with lodging, flights, and car rentals to book and manage trips.

FintechMarketplacesSaaSTravel & Hospitality

Elia(CEO)Elia Wallen(Founder)Petar Besevic(Founder)Simon Spurrier(Founder)

Co-investorsElefundTelescope PartnersEntrepreneur First

Gringrin.noinMay 2025 · $140M

Revore builds return and collection systems for reusable packaging and other returnable items, deployed at indoor sites such as offices, airports, universities, hospitals, pharmacies, retail chains, quick-service restaurants, and event arenas.

Circular EconomyCleantechHardware

Co-investorsHeadlineKickstart InnovationBond Capital ManagementBullpen Capitallone pine capital

Imagoimagobio.comin𝕏Nov 2020 · $80Macquired by Merck

A pharmaceutical company that develops medicines and vaccines, with research pipelines and clinical trials aimed at new treatments.

BiotechHealthtech

Co-investorsFrazier Life SciencesHighlight CapitalMRL Ventures FundXeraya CapitalAmgen VenturesBlackRock+5 more

LRNlrn.com

LRN provides ethics and compliance software, analytics, and training that help organizations manage policies, employee reporting, codes of conduct, and regulatory compliance programs.

EdTechEnterprise SoftwareSaaS

Dov Seidman(Founder)

Co-investorsInsight Partners

Modernamodernatx.comin𝕏Aug 2016

Moderna develops mRNA-based medicines for infectious and serious diseases using its proprietary mRNA platform and design technology.

BiotechDeep TechMedical DevicesCambridge, US

Robert Langer(Founder)Noubar Afeyan, Ph.D.(Co-founder and Chairman, Moderna; CEO, Flagship Pioneering)Lorence Kim(Executive Officer)inJames R. Kasinger(Executive Officer)inStephen Hoge(Executive Officer)inDerrick Rossi(Founder)

Co-investorsAglae VenturesFlagship PioneeringFPVKhosla VenturesLingottoPremji Invest+5 more

Molliemollie.comin𝕏

Mollie provides in-person payment tools for European businesses, including card terminals, mobile and fixed POS terminals, and tap-to-pay apps for iPhone and Android, all managed through a central dashboard.

E-commerceFintechRetail TechSaaS

Adriaan Mol(Founder)in

Co-investorsAlkeon InnovationFelicis VenturesGeneral AtlanticKeen Venture PartnersTCVAlkeon Capital+2 more

Nongfu Springnongfuspring.com

Zhong Shanshan(Founder)

Norm Ainorm.aiin

Norm Ai builds AI agents that automate legal and compliance tasks for large institutions, along with a verification layer for AI agents and an affiliated AI-native law firm.

AI & Machine LearningEnterprise SoftwareLegalTechNew York, US

John Nay(Founder)inMike Schmidtberger(Chairman and Partner, Norm Law)in

Co-investorsBain Capital VenturesCoatue ManagementCraft VenturesKhosla VenturesBain CapitalBlackstone+11 more

Open Evidenceopenevidence.com

AI company developing a medical search engine used by physicians for clinical decision support.

Daniel Nadler(Founder)inZachary Ziegler(Founder)Daniel Nadler Zachary Ziegler(Founder)Zack Ziegler(Founder)

Co-investorsAlkeon InnovationAmity VenturesAndreessen HorowitzBas1s VenturesBond Capital ManagementBreyer Capital+26 more

Talaris Therapeuticstalaristx.comApr 2019

Clinical-stage biotech developing cell therapy products for transplant and autoimmune conditions

BiotechLouisville, US

Suzanne Ildstad(Executive Officer, Director)Scott Requadt(Executive Officer, Director)Geoff Mackay(Director)Francois Nader(Director)

BoardSandip Agarwala(Director)inMark McDade(Director)in

Co-investorsAisling CapitalKeyhorse CapitalLongitude CapitalQiming Venture Partners USAViking GlobalCitadel+3 more

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

AlnylamAnthos Therapeutics, Inc.

Exits · 3

2 IPOs · 1 acquisitions

Alnylam PharmaceuticalsNASDAQ: ALNYApogee TherapeuticsNASDAQ: APGEImagoacq. by Merck

Portfolio news

latest coverage across their companies

Frequently asked questions

How many investments has Blackstone Life Sciences made?
Blackstone Life Sciences has 20 tracked investments, 3 of which have exited, including 5 dated in the last 24 months.
What stage does Blackstone Life Sciences invest at?
Blackstone Life Sciences invests at the Series A, Series B, Series C, Growth, Late Stage stages.
What is Blackstone Life Sciences's typical check size?
Blackstone Life Sciences typically writes checks of $20M – $60M.
What sectors does Blackstone Life Sciences focus on?
Blackstone Life Sciences focuses on AI & Machine Learning, Biotech, Crypto & Web3, Digital Health, Energy, Healthtech, Longevity, Medical Devices, PropTech, Sector Agnostic.
Where is Blackstone Life Sciences located?
Blackstone Life Sciences is headquartered in New York, US.
Who does Blackstone Life Sciences co-invest with?
Blackstone Life Sciences most often shares deals with ARCH Venture Partners, Atlas Venture, Cardinal Partners, among 15 tracked co-investors.

Images

Blackstone Life Sciences photoBlackstone Life Sciences photoBlackstone Life Sciences photo

Similar investors

Featured in lists